Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

Summary

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.

Timeline

Start

2025-12-17

Primary completion

2026-11-30

Completion

2027-05-30

Drugs

Indications